Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma

Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of oncology 2023, Vol.2023, p.4616682-11
Hauptverfasser: Lu, Ying, Yang, Jinjin, Zhu, Junwen, Shu, Yao, Zou, Xuan, Ruan, Qiao, Luo, Shuyuan, Wang, Yong, Wen, Jun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 11
container_issue
container_start_page 4616682
container_title Journal of oncology
container_volume 2023
creator Lu, Ying
Yang, Jinjin
Zhu, Junwen
Shu, Yao
Zou, Xuan
Ruan, Qiao
Luo, Shuyuan
Wang, Yong
Wen, Jun
description Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.
doi_str_mv 10.1155/2023/4616682
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3106038583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3104856279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1952-516fd665766caa544867f94b4691e190c59a21a8bb89a509ae5a25fcd7b4db703</originalsourceid><addsrcrecordid>eNp90M1LwzAYBvAgipsfN89S8CLoXJImaXIcRZ0w2cF5Lm_TlGW0zda0yv57O1pFPHjKG_jx8PAgdEXwAyGcTymm4ZQJIoSkR2hMhIwmknF8_OseoTPvNxgLhpU4RaNQUUkp5WO0mmUfUGnjA1sFzdoEc-sbV5lgpk2zL6CxrgpeXWZzq_vP4JY1FMHbroXStT6ITVEEMdTaVq6EC3SSQ-HN5fCeo_enx1U8nyyWzy_xbDHRRHE64UTkmRA8EkIDcMakiHLFUiYUMURhzRVQAjJNpQKOFRgOlOc6i1KWpREOz9Ftn7ut3a41vklK63VXBSrTtUpCggUOJZdhR2_-0I1r66prd1BMckEj1an7XunaeV-bPNnWtoR6nxCcHNZODmsnw9odvx5C27Q02Q_-nrcDdz1Y2yqDT_t_3BdF-oTc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3104856279</pqid></control><display><type>article</type><title>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</title><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lu, Ying ; Yang, Jinjin ; Zhu, Junwen ; Shu, Yao ; Zou, Xuan ; Ruan, Qiao ; Luo, Shuyuan ; Wang, Yong ; Wen, Jun</creator><contributor>Feng, Zhi-En ; Zhi-En Feng</contributor><creatorcontrib>Lu, Ying ; Yang, Jinjin ; Zhu, Junwen ; Shu, Yao ; Zou, Xuan ; Ruan, Qiao ; Luo, Shuyuan ; Wang, Yong ; Wen, Jun ; Feng, Zhi-En ; Zhi-En Feng</creatorcontrib><description>Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>EISSN: 1687-8469</identifier><identifier>DOI: 10.1155/2023/4616682</identifier><identifier>PMID: 39282225</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Cancer therapies ; Cell cycle ; Cell growth ; Chromatin ; DNA damage ; DNA methylation ; Enzymes ; Epigenetics ; Kinases ; Medical prognosis ; Metabolism ; Metabolites ; Metastasis ; Proteins ; Signal transduction ; Squamous cell carcinoma ; Tumorigenesis</subject><ispartof>Journal of oncology, 2023, Vol.2023, p.4616682-11</ispartof><rights>Copyright © 2023 Ying Lu et al.</rights><rights>Copyright © 2023 Ying Lu et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1952-516fd665766caa544867f94b4691e190c59a21a8bb89a509ae5a25fcd7b4db703</cites><orcidid>0000-0001-8989-1927 ; 0000-0002-0456-8862 ; 0000-0002-6437-0567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39282225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Feng, Zhi-En</contributor><contributor>Zhi-En Feng</contributor><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Yang, Jinjin</creatorcontrib><creatorcontrib>Zhu, Junwen</creatorcontrib><creatorcontrib>Shu, Yao</creatorcontrib><creatorcontrib>Zou, Xuan</creatorcontrib><creatorcontrib>Ruan, Qiao</creatorcontrib><creatorcontrib>Luo, Shuyuan</creatorcontrib><creatorcontrib>Wang, Yong</creatorcontrib><creatorcontrib>Wen, Jun</creatorcontrib><title>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.</description><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Chromatin</subject><subject>DNA damage</subject><subject>DNA methylation</subject><subject>Enzymes</subject><subject>Epigenetics</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metastasis</subject><subject>Proteins</subject><subject>Signal transduction</subject><subject>Squamous cell carcinoma</subject><subject>Tumorigenesis</subject><issn>1687-8450</issn><issn>1687-8450</issn><issn>1687-8469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp90M1LwzAYBvAgipsfN89S8CLoXJImaXIcRZ0w2cF5Lm_TlGW0zda0yv57O1pFPHjKG_jx8PAgdEXwAyGcTymm4ZQJIoSkR2hMhIwmknF8_OseoTPvNxgLhpU4RaNQUUkp5WO0mmUfUGnjA1sFzdoEc-sbV5lgpk2zL6CxrgpeXWZzq_vP4JY1FMHbroXStT6ITVEEMdTaVq6EC3SSQ-HN5fCeo_enx1U8nyyWzy_xbDHRRHE64UTkmRA8EkIDcMakiHLFUiYUMURhzRVQAjJNpQKOFRgOlOc6i1KWpREOz9Ftn7ut3a41vklK63VXBSrTtUpCggUOJZdhR2_-0I1r66prd1BMckEj1an7XunaeV-bPNnWtoR6nxCcHNZODmsnw9odvx5C27Q02Q_-nrcDdz1Y2yqDT_t_3BdF-oTc</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Lu, Ying</creator><creator>Yang, Jinjin</creator><creator>Zhu, Junwen</creator><creator>Shu, Yao</creator><creator>Zou, Xuan</creator><creator>Ruan, Qiao</creator><creator>Luo, Shuyuan</creator><creator>Wang, Yong</creator><creator>Wen, Jun</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8989-1927</orcidid><orcidid>https://orcid.org/0000-0002-0456-8862</orcidid><orcidid>https://orcid.org/0000-0002-6437-0567</orcidid></search><sort><creationdate>2023</creationdate><title>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</title><author>Lu, Ying ; Yang, Jinjin ; Zhu, Junwen ; Shu, Yao ; Zou, Xuan ; Ruan, Qiao ; Luo, Shuyuan ; Wang, Yong ; Wen, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1952-516fd665766caa544867f94b4691e190c59a21a8bb89a509ae5a25fcd7b4db703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Chromatin</topic><topic>DNA damage</topic><topic>DNA methylation</topic><topic>Enzymes</topic><topic>Epigenetics</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metastasis</topic><topic>Proteins</topic><topic>Signal transduction</topic><topic>Squamous cell carcinoma</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Yang, Jinjin</creatorcontrib><creatorcontrib>Zhu, Junwen</creatorcontrib><creatorcontrib>Shu, Yao</creatorcontrib><creatorcontrib>Zou, Xuan</creatorcontrib><creatorcontrib>Ruan, Qiao</creatorcontrib><creatorcontrib>Luo, Shuyuan</creatorcontrib><creatorcontrib>Wang, Yong</creatorcontrib><creatorcontrib>Wen, Jun</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Ying</au><au>Yang, Jinjin</au><au>Zhu, Junwen</au><au>Shu, Yao</au><au>Zou, Xuan</au><au>Ruan, Qiao</au><au>Luo, Shuyuan</au><au>Wang, Yong</au><au>Wen, Jun</au><au>Feng, Zhi-En</au><au>Zhi-En Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2023</date><risdate>2023</risdate><volume>2023</volume><spage>4616682</spage><epage>11</epage><pages>4616682-11</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><eissn>1687-8469</eissn><abstract>Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>39282225</pmid><doi>10.1155/2023/4616682</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8989-1927</orcidid><orcidid>https://orcid.org/0000-0002-0456-8862</orcidid><orcidid>https://orcid.org/0000-0002-6437-0567</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-8450
ispartof Journal of oncology, 2023, Vol.2023, p.4616682-11
issn 1687-8450
1687-8450
1687-8469
language eng
recordid cdi_proquest_miscellaneous_3106038583
source PubMed Central Open Access; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Cancer therapies
Cell cycle
Cell growth
Chromatin
DNA damage
DNA methylation
Enzymes
Epigenetics
Kinases
Medical prognosis
Metabolism
Metabolites
Metastasis
Proteins
Signal transduction
Squamous cell carcinoma
Tumorigenesis
title Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A47%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20the%20Histone%20Acetylation%20Modification%20in%20the%20Oral%20Squamous%20Cell%20Carcinoma&rft.jtitle=Journal%20of%20oncology&rft.au=Lu,%20Ying&rft.date=2023&rft.volume=2023&rft.spage=4616682&rft.epage=11&rft.pages=4616682-11&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2023/4616682&rft_dat=%3Cproquest_cross%3E3104856279%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3104856279&rft_id=info:pmid/39282225&rfr_iscdi=true